Amendment: Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)

Notice Number: NOT-AI-11-035

Release Date: February 25, 2011

National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

The purpose of this Notice is to amend and clarify wording in Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21), PAS-10-148.

Located under Section I. Funding Opportunity Description, 1. Research Objectives, Section: Research Objectives and Scope, third bulleted list:

Research areas NOT appropriate for this FOA include studies of:

• Immunodeficiency resulting from infection (e.g., HIV);
• Immunodeficiency resulting from treatments (e.g., chemotherapy), exposures (e.g., radiation), or therapies (e.g., transplantation, or surgery);
• Immunodeficiency resulting from aging or immaturity; and
• Basic immunologic mechanisms unless related to understanding of primary immunodeficiency disease.

This replaces:

Research areas appropriate for this FOA include studies of:

• Immunodeficiency resulting from infection (e.g., HIV);
• Immunodeficiency resulting from treatments (e.g., chemotherapy), exposures (e.g., radiation), or therapies (e.g., transplantation, or surgery);
• Immunodeficiency resulting from aging or immaturity; and
• Basic immunologic mechanisms unless related to understanding of primary immunodeficiency disease.

All other aspects of this FOA remains unchanged.

Please direct all inquiries to:

David R. Johnson, Ph.D. 
Division of Allergy, Immunology and Transplantation 
National Institute of Allergy and Infectious Diseases
Room 6714-B, MSC-6601
6610 Rockledge Drive
Bethesda, MD 20892-6601
Telephone: (301) 496-7104
Fax: (301) 480-1899
Email: drjohnson@niaid.nih.gov